Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Appointed director Quarterly results
|
ACELRX PHARMACEUTICALS INC (ACRX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/10/2023 |
8-K
| Quarterly results |
05/10/2023 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
08/11/2022 |
8-K
| Quarterly results |
05/16/2022 |
8-K
| Quarterly results |
03/10/2022 |
8-K
| Quarterly results |
11/15/2021 |
8-K
| Quarterly results |
08/16/2021 |
8-K
| Quarterly results |
11/05/2020 |
8-K
| Quarterly results |
08/10/2020 |
8-K
| Quarterly results |
05/11/2020 |
8-K
| Quarterly results |
03/16/2020 |
8-K
| Quarterly results |
11/06/2019 |
8-K
| Quarterly results |
08/05/2019 |
8-K
| Quarterly results |
05/08/2019 |
8-K
| Quarterly results |
11/02/2018 |
8-K
| Quarterly results |
08/02/2018 |
8-K
| Quarterly results |
08/01/2017 |
8-K
| Quarterly results |
10/29/2015 |
8-K
| Quarterly results |
11/10/2014 |
8-K
| Quarterly results
Docs:
|
"AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results REDWOOD CITY, Calif., November 10, 2014 - AcelRx Pharmaceuticals, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2014. “In the third quarter, we held a meeting with the FDA to discuss the Zalviso CRL received in July. During the meeting we discussed the resubmission of the Zalviso NDA and the steps necessary for the resubmission,” stated Richard King, president and CEO of AcelRx. “In advance of resubmitting our Zalviso NDA, we have agreed with the FDA to submit protocols for the bench testing and a Human Factors Study for t..." |
|
03/05/2014 |
8-K
| Quarterly results
Docs:
|
"AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results REDWOOD CITY, Calif., March 3, 2014 - AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. “AcelRx made strong progress in 2013 with the successful completion of the Zalviso™ Phase 3 program, the filing and acceptance of the NDA for Zalviso, the execution of a commercial partnership agreement with Grunenthal for Zalviso that covers Europe and Australia, and agreement with FDA on a Phase 3 program for ARX-04, an investigational single-dose sublingual sufentanil NanoTab for moderate-to-se..." |
|
05/09/2013 |
8-K
| Quarterly results |
03/13/2013 |
8-K
| Form 8-K - Current report |
11/06/2012 |
8-K
| Quarterly results |
08/13/2012 |
8-K
| Quarterly results |
05/08/2012 |
8-K
| Quarterly results |
03/21/2012 |
8-K
| Quarterly results |
11/08/2011 |
8-K
| Form 8-K - Current report |
08/12/2011 |
8-K
| Form 8-K - Current report |
05/16/2011 |
8-K
| Form 8-K - Current report |
03/25/2011 |
8-K
| Form 8-K - Current report |
|
|